Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
17.51
-0.79 (-4.32%)
Mar 27, 2025, 4:00 PM EST - Market closed
Telix Pharmaceuticals Revenue
In the year 2024, Telix Pharmaceuticals had annual revenue of 783.21M AUD with 55.85% growth. Telix Pharmaceuticals had revenue of 209.62M in the quarter ending December 31, 2024, with 48.82% growth.
Revenue (ttm)
783.21M AUD
Revenue Growth
+55.85%
P/S Ratio
12.10
Revenue / Employee
1,887,246 AUD
Employees
415
Market Cap
5.87B undefined
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 783.21M | 280.66M | 55.85% |
| Dec 31, 2023 | 502.55M | 342.45M | 213.90% |
| Dec 31, 2022 | 160.10M | 152.50M | 2,007.64% |
| Dec 31, 2021 | 7.60M | 2.38M | 45.71% |
| Dec 31, 2020 | 5.21M | 1.73M | 49.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TLX News
- 6 days ago - Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent - Investopedia
- 6 days ago - FDA Approves New Prostate Cancer Imaging Agent Gozellix® - GlobeNewsWire
- 10 days ago - Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America - GlobeNewsWire
- 15 days ago - Telix Adds Lead-212 Isotope Production Capability - GlobeNewsWire
- 24 days ago - Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - GlobeNewsWire
- 4 weeks ago - FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review - GlobeNewsWire
- 4 weeks ago - Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami - GlobeNewsWire
- 5 weeks ago - Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast - Reuters